Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 07, 2020; 94 (14) Resident & Fellow Section

Pearls & Oy-sters: Fatal brain edema is a rare complication of severe CACNA1A-related disorder

Laurence Gauquelin, Cynthia Hawkins, Emily W.Y. Tam, Steven P. Miller, Grace Yoon
First published March 13, 2020, DOI: https://doi.org/10.1212/WNL.0000000000009223
Laurence Gauquelin
From the Division of Clinical and Metabolic Genetics (L.G., G.Y.) and Division of Neurology (L.G., E.W.Y.T., S.P.M., G.Y.), Department of Paediatrics, and Division of Pathology, Department of Paediatric Laboratory Medicine (C.H.), The Hospital for Sick Children, University of Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Hawkins
From the Division of Clinical and Metabolic Genetics (L.G., G.Y.) and Division of Neurology (L.G., E.W.Y.T., S.P.M., G.Y.), Department of Paediatrics, and Division of Pathology, Department of Paediatric Laboratory Medicine (C.H.), The Hospital for Sick Children, University of Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily W.Y. Tam
From the Division of Clinical and Metabolic Genetics (L.G., G.Y.) and Division of Neurology (L.G., E.W.Y.T., S.P.M., G.Y.), Department of Paediatrics, and Division of Pathology, Department of Paediatric Laboratory Medicine (C.H.), The Hospital for Sick Children, University of Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven P. Miller
From the Division of Clinical and Metabolic Genetics (L.G., G.Y.) and Division of Neurology (L.G., E.W.Y.T., S.P.M., G.Y.), Department of Paediatrics, and Division of Pathology, Department of Paediatric Laboratory Medicine (C.H.), The Hospital for Sick Children, University of Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Yoon
From the Division of Clinical and Metabolic Genetics (L.G., G.Y.) and Division of Neurology (L.G., E.W.Y.T., S.P.M., G.Y.), Department of Paediatrics, and Division of Pathology, Department of Paediatric Laboratory Medicine (C.H.), The Hospital for Sick Children, University of Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Pearls & Oy-sters: Fatal brain edema is a rare complication of severe CACNA1A-related disorder
Laurence Gauquelin, Cynthia Hawkins, Emily W.Y. Tam, Steven P. Miller, Grace Yoon
Neurology Apr 2020, 94 (14) 631-634; DOI: 10.1212/WNL.0000000000009223

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1064

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Pearls

  • Heterozygous pathogenic variants in CACNA1A are associated with 3 classic phenotypes, with variable expression and significant overlap: familial hemiplegic migraine 1, spinocerebellar ataxia 6, and episodic ataxia type 2.

  • In addition to the 3 classic phenotypes, there is a more recently described fourth rare and severe presentation characterized by early-onset permanent cerebellar ataxia, developmental delays, seizures, and episodic attacks resembling hemiplegic migraine.

  • The severe subtype of CACNA1A-related disorder can be associated with refractory, fatal brain edema.

Oy-sters

  • CACNA1A-related disorder should be considered in the differential diagnosis of childhood-onset ataxia associated with isolated cerebellar atrophy on brain imaging, even in the absence of episodic clinical manifestations.

  • CACNA1A-related disorder can mimic an immune-mediated process and should be considered in cases of acute refractory brain edema of unclear etiology.

  • A timely and accurate diagnosis of CACNA1A-related disorder has treatment implications; corticosteroids are beneficial during the acute phase of cerebral edema, and attacks may potentially be prevented by early treatment with acetazolamide.

A 5-year-old girl initially presented in the first months of life with hypotonia and eye movement abnormalities. She had instability of primary gaze and saccadic smooth pursuit, and there was evidence of ocular motor apraxia. She then developed cerebellar ataxia, dysarthria, and generalized dystonia. Posturing was most noticeable in the lower extremities. Ataxia was severe, and the patient never walked independently. She did not have any type of headache, and her family history was noncontributory. Brain MRI revealed isolated cerebellar vermis atrophy (figure).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Neuroimaging and histopathologic features of severe CACNA1A-related disorder

(A–D) Brain MRI obtained at age 5 years, on day 2 (A, B) and day 10 (C, D) of admission. (A) Sagittal T1 image shows atrophy of the cerebellar vermis; (B) axial fluid-attenuated inversion recovery (FLAIR) image shows increased signal and size of the right hippocampus (arrow); (C) axial FLAIR image shows cortical hyperintensities; (D) axial diffusion-weighted imaging sequence shows multiple cortical foci of restricted diffusion with a frontoparietal predominance (corresponding apparent diffusion coefficient map not shown). (E–H) Neuropathologic findings. (E) Gross image of the brain shows the small cerebellum and brainstem; (F) midsagittal section of the brainstem and cerebellum highlights the small vermis and cerebellar hemisphere; (G) whole mount of the cerebellar hemisphere shows atrophy of the folia; (H) higher power image of the cerebellar folia shows complete loss of Purkinje cells and external granular cell layer with gliosis.

At age 3 years, the patient had a first episode of decreased level of consciousness in the context of fever. She was diagnosed with focal seizures, with left temporal epileptiform interictal discharges on EEG, and signal changes in the left hippocampus on brain MRI. She was treated with levetiracetam, which was later weaned after 2 years of seizure freedom.

The patient was admitted to the intensive care unit at our hospital at age 5 years with a second episode of altered mental status following a minor fall. She was found to be comatose, with prolonged seizures, exacerbated generalized dystonia, and unexplained fevers. CSF studies were unremarkable. Creatine kinase increased to 4,939 U/L (laboratory reference range 75–230) and then returned to normal within 48 hours. EEG revealed right temporal as well as generalized periodic discharges, superimposed on diffuse background slowing. Levetiracetam was restarted, and dystonia was treated with baclofen. Brain imaging was repeated and showed new findings of T2 and fluid-attenuated inversion recovery hypersignal, increased size of the right hippocampus, and multiple foci of cortical diffusion restriction involving both hemispheres, with a frontoparietal predominance (figure, B–D). There was mild interhemispheric pachymeningeal enhancement, but no definitive leptomeningeal enhancement and no parenchymal enhancement. Magnetic resonance spectroscopy was normal.

Despite complete seizure control, the patient remained encephalopathic and continued to require significant ventilatory support. She received pulse steroids (methylprednisolone 30 mg/kg/dose) from day 5 until day 9 of admission. On day 8, she was found to have a fixed dilated right pupil. Repeat brain imaging showed diffuse edema and bilateral uncal herniation, with low N-acetylaspartate peak and a probable lactate peak on spectroscopy. Intracranial pressure monitoring revealed an initial pressure of 31 mm Hg (normal 3–7 mm Hg in young children). The patient received multiple doses of mannitol in addition to continuous infusion of hypertonic saline over days 8, 9, and 10 of admission. A trial of IV immunoglobulins was started on day 9 given the possibility of an immune-mediated process. On day 10, while on maximal medical treatment for intracranial hypertension, the patient was found to have bilateral fixed dilated pupils with persistent global swelling on repeat brain imaging. A decision was made to withdraw life-sustaining measures, and she died on day 10 of admission.

Chromosomal microarray, metabolic investigations, and a comprehensive brain malformation gene panel had all previously been normal. Skin and muscle biopsy were obtained during the admission at our hospital and were normal. Whole exome sequencing was also pursued and revealed a de novo heterozygous pathogenic variant in the CACNA1A gene (c.5000G>C, p.R1667P) after death.

Postmortem brain biopsy and neuropathologic examination were performed (figure, E–H). The cerebellar vermis and hemispheres appeared atrophic without any other focal lesion within the brainstem. There was complete loss of Purkinje cells. Hemorrhagic lesions involving the cerebral cortex were seen in the right occipital lobe.

Discussion

Heterozygous pathogenic variants in CACNA1A, encoding the α1A subunit of the neuronal P/Q-type voltage-gated calcium channel, are associated with 3 classic phenotypes, with variable expression and significant overlap: familial hemiplegic migraine 1, spinocerebellar ataxia 6, and episodic ataxia type 2.1 More recently, a fourth rare and severe presentation was described, characterized by early-onset permanent cerebellar ataxia, developmental delays, seizures, and episodic attacks resembling hemiplegic migraine.2,–,6

It is well-established that episodes of CACNA1A-related hemiplegic migraine can be triggered by minor head trauma and can be associated with altered mental status.1,6 In addition, there are a few reports in the literature of severe CACNA1A-related disorder presenting with episodes of prolonged coma, with reversible cerebral edema.4,5,7 These dramatic attacks were previously thought to be specific to the S218L variant but have now been associated with several other CACNA1A pathogenic variants.3 Our patient carried a de novo missense variant (c.5000G>C, p.R1667P) that has not previously been reported, but is absent from large population databases.

This is the second report of fatal delayed cerebral edema associated with CACNA1A-related disorder.3 This phenotype likely represents the most severe end of the disease spectrum. The mechanisms for brain edema in CACNA1A-related disorder are hypothesized to include a cytotoxic response through dysfunction of the neuronal voltage-gated calcium channels.3,8 Aberrant neurotransmitter release has also been described.9

During the most recent acute attack, the clinical features of our patient included fever and seizures. Together with the imaging findings of hippocampal signal changes and cerebral edema, the clinical picture was believed to be suspicious for inflammatory/immune-mediated causes, prompting trials of pulse steroids and IV immunoglobulins. The genetic diagnosis was not known at the time. It appears that severe CACNA1A-related disorder can mimic immune-mediated processes or even stroke-like episodes, and should be considered in cases of acute refractory brain edema of unclear etiology.

In addition to intracranial hypertension management (e.g., hypertonic saline, mannitol), treatment with corticosteroids has been reported to be beneficial in a few cases of cerebral edema associated with acute attacks in CACNA1A-related disorder.2,4,6 The effect of corticosteroids may be through indirect inhibition of the voltage-dependent calcium channels and by reducing cortical spreading depression.4 However, despite pulse methylprednisolone and aggressive intracranial hypertension management, the edema and mass effect progressed rapidly in our patient.

In episodic ataxia type 2, acetazolamide was previously found to be effective in reducing attack frequency.1 Familial hemiplegic migraine is also reported to respond to acetazolamide, flunarizine, verapamil, sodium valproate, or lamotrigine.10 In the severe phenotypic subtype of CACNA1A-related disorder, results have been inconsistent, with only a few case reports suggesting a benefit of verapamil or acetazolamide.3,7

Our patient had initially presented several years before the fatal episode with hypotonia and prominent cerebellar signs, with evidence on brain MRI of isolated cerebellar vermis atrophy. CACNA1A-related disorder is known to be associated with isolated cerebellar atrophy, and should be considered in the differential diagnosis of childhood-onset ataxia with this brain imaging finding, even in the absence of episodic clinical manifestations. An early diagnosis of CACNA1A-related disorder could allow clinicians to consider a trial of preventative medication. Although there is no evidence that such medication would change the outcome, a trial appears reasonable given the severity of acute attacks in patients with the severe phenotypic subtype.

This report illustrates an atypical and severe presentation of a rare genetic disorder. The phenotypic spectrum of CACNA1A-related disorder is broad, and this diagnosis carries important management implications.

Study funding

No targeted funding reported.

Disclosure

L. Gauquelin, C. Hawkins, and E.W.Y. Tam report no disclosures. S.P. Miller is supported by the Bloorview Children's Hospital Chair in Paediatric Neuroscience. G. Yoon reports no disclosures. Go to Neurology.org/N for full disclosures.

Acknowledgment

L. Gauquelin has received grants from the Canadian Gene Cure Advanced Therapies for Rare Disease (Can-GARD) and from the R.S. McLaughlin and Teva Canada Innovation funds from the Faculty of Medicine, Université Laval. S.P. Miller is supported by the Bloorview Children's Hospital Chair in Paediatric Neuroscience.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • © 2020 American Academy of Neurology

References

  1. 1.↵
    1. Terwindt GM,
    2. Ophoff RA,
    3. Haan J, et al
    . Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine: Dutch Migraine Genetics Research Group. Neurology 1998;50:1105–1110.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Sanchez-Albisua I,
    2. Schoning M,
    3. Jurkat-Rott K,
    4. Lerche H
    . Possible effect of corticoids on hemiplegic attacks in severe hemiplegic migraine. Pediatr Neurol 2013;49:286–288.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kors EE,
    2. Terwindt GM,
    3. Vermeulen FL, et al
    . Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol 2001;49:753–760.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Camia F,
    2. Pisciotta L,
    3. Morana G, et al
    . Combined early treatment in hemiplegic attacks related to CACNA1A encephalopathy with brain oedema: blocking the cascade? Cephalalgia 2017;37:1202–1206.
    OpenUrl
  5. 5.↵
    1. Vahedi K,
    2. Denier C,
    3. Ducros A, et al
    . CACNA1A gene de novo mutation causing hemiplegic migraine, coma, and cerebellar atrophy. Neurology 2000;55:1040–1042.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Curtain RP,
    2. Smith RL,
    3. Ovcaric M,
    4. Griffiths LR
    . Minor head trauma-induced sporadic hemiplegic migraine coma. Pediatr Neurol 2006;34:329–332.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Asghar SJ,
    2. Milesi-Halle A,
    3. Kaushik C,
    4. Glasier C,
    5. Sharp GB
    . Variable manifestations of familial hemiplegic migraine associated with reversible cerebral edema in children. Pediatr Neurol 2012;47:201–204.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Chabriat H,
    2. Vahedi K,
    3. Clark CA, et al
    . Decreased hemispheric water mobility in hemiplegic migraine related to mutation of CACNA1A gene. Neurology 2000;54:510–512.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kaja S,
    2. Van de Ven RC,
    3. Broos LA, et al
    . Severe and progressive neurotransmitter release aberrations in familial hemiplegic migraine type 1 Cacna1a S218L knock-in mice. J Neurophysiol 2010;104:1445–1455.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Pelzer N,
    2. Stam AH,
    3. Haan J,
    4. Ferrari MD,
    5. Terwindt GM
    . Familial and sporadic hemiplegic migraine: diagnosis and treatment. Curr Treat Options Neurol 2013;15:13–27.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Pearls
    • Oy-sters
    • Discussion
    • Study funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • Resident & Fellow Rounds

Topics Discussed

  • Migraine
  • Cerebellum
  • Coma
  • Spinocerebellar ataxia
  • Ion channel gene defects

Alert Me

  • Alert me when eletters are published
Neurology: 99 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise